RB1 and prostate carcinoma: Recently we reported that a novel peptide coupled to penetratin (PEP), was cytotoxic at low micro molar concentrations to tumors that overexpress activating E2Fs, including Burkitt lymphoma cells, pRB negative small cell lung cancer (SCLC) cells and DU145 prostate cancer cells.